mash and glp 1 Unequivocally yes': therapies still needed despite boom in GLP-1 use in liver disease GLP-1 BREAKTHROUGH: FDA APPROVES TREATMENT
Description
Refund requests are frequently ignored, and customer service becomes unresponsive after purchase
Companies including Aspen Pharmacare, Vimy Pharma, and others have indicated summer 2026 launch targets for their generic versions
You may have heard of it by its brand names, Zepbound or Mounjaro
And 15% of those polled said they've used the drugs at some point, which is an increase of 9 percentage points over 2024
[DOI] [PMC free article] [PubMed] [Google Scholar] 185.Aroda V.R., Ratner R
